Neil Josephson - 10 Mar 2022 Form 4 Insider Report for Zymeworks Inc.

Role
Chief Medical Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
10 Mar 2022
Net transactions value
$0
Form type
4
Filing time
11 Mar 2022, 20:00:13 UTC
Previous filing
11 Jan 2022
Next filing
05 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Shares Options Exercise $0 +729 +10% $0.000000 7,848 10 Mar 2022 Direct F1
transaction ZYME Common Shares Options Exercise $0 +1,666 +21% $0.000000 9,514 10 Mar 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -729 -50% $0.000000 730 10 Mar 2022 Common Shares 729 Direct F3, F4
transaction ZYME Restricted Stock Unit Options Exercise $0 -1,666 -33% $0.000000 3,334 10 Mar 2022 Common Shares 1,666 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
F2 Represents common shares issued upon vesting of one third of the RSUs granted on March 10, 2021.
F3 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F4 The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
F5 The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022.